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Abstract
A prominent feature of Parkinson’s disease (PD) is the loss of dopamine in the striatum, and many therapeutic interventions
for the disease are aimed at restoring dopamine signaling. Dopamine signaling includes the synthesis, storage, release, and
recycling of dopamine in the presynaptic terminal and activation of pre- and post-synaptic receptors and various
downstream signaling cascades. As an aid that might facilitate our understanding of dopamine dynamics in the
pathogenesis and treatment in PD, we have begun to merge currently available information and expert knowledge
regarding presynaptic dopamine homeostasis into a computational model, following the guidelines of biochemical systems
theory. After subjecting our model to mathematical diagnosis and analysis, we made direct comparisons between model
predictions and experimental observations and found that the model exhibited a high degree of predictive capacity with
respect to genetic and pharmacological changes in gene expression or function. Our results suggest potential approaches
to restoring the dopamine imbalance and the associated generation of oxidative stress. While the proposed model of
dopamine metabolism is preliminary, future extensions and refinements may eventually serve as an in silico platform for
prescreening potential therapeutics, identifying immediate side effects, screening for biomarkers, and assessing the impact
of risk factors of the disease.
Citation: Qi Z, Miller GW, Voit EO (2008) Computational Systems Analysis of Dopamine Metabolism. PLoS ONE 3(6): e2444. doi:10.1371/journal.pone.0002444
Editor: Kenji Hashimoto, Chiba University Center for Forensic Mental Health, Japan
Received March 10, 2008; Accepted April 29, 2008; Published June 18, 2008
Copyright:  2008 Qi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a Woodruff Health Science Center Fund grant, NIH grant number U54-ES012068, and an endowment from the Georgia
Research Alliance.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: eberhard.voit@bme.gatech.edu
Introduction
Parkinson’s disease (PD) is the most common neurodegenerative
movement disorder, affecting more than 1% of the worldwide
population over the age of 65 [1,2]. Pathologically, PD is
characterized by a progressive loss of dopamine neurons in the
substantia nigra pars compacta, the presence of ubiquitin- and alpha-
synuclein-positive cytoplasmic inclusions known as Lewy bodies
[3,4], depigmentation of the locus ceruleus, and autonomic
dysfunction including sympathetic denervation of the heart [5].
While PD is a complex, multi-faceted disease, it has been suggested
that neurodegeneration is primarily due to the generation of toxic
species and to oxidative stress caused by abnormal dopamine
metabolism [6–9]. Because loss of dopamine is responsible for the
majority of the motor symptoms of PD, treatment options have
mostly been based upon restoration of dopamine function by
replacement of dopamine precursors, inhibition of degradative
enzymes, or dopamine agonists. Some efforts have also been
targeted toward the development of drugs for PD based on the
synergistic action of dopamine, glutamate, and acetylcholine
neurotransmission on GABAergic neurons in the striatum [10–14].
For many years, there has been considerable debate as to
whether L-DOPA, administered to treat the symptoms of PD, may
actually be exacerbating the disease due to oxidation of L-DOPA
and its metabolites. In addition, L-DOPA treatment, which should
counteract decreases in dopamine, tends to become ineffective
after a while, again demonstrating the complexity of the
controlled, adaptive metabolic system. Given the inherent
complexity of dopamine dynamics and the redox state of the
neuron, a quantitative analysis using mathematical models could
enhance our understanding of these complicated processes.
To our knowledge, no dynamic model of presynaptic dopamine
homeostasis is available outside the one proposed here. Some
investigators have developed models for various aspects of
dopamine function [15,16], while others have elucidated some of
the context in which dopamine metabolism affects PD, schizo-
phrenia, opium addiction and other pathologies with focus on
functions and processes on postsynaptic site, and specifically the
role of DARPP-32 [14,17–20]. We therefore set out to design a
mathematical model of dopamine metabolism/homeostasis de novo.
The focus on dopamine was chosen not only because of its
common role in Parkinson’s disease and other disorders, but also
because of its key role as a physiologically, pathologically, and
pharmacologically interesting neurotransmitter. The resulting
model turned out to provide qualitatively reasonable and even
semi-quantitatively accurate predictions of critical systemic
responses of the dopamine metabolism and may eventually serve
as a computational platform for rational drug development and
biomarker screening for PD.
Materials and Methods
The design of a pathway model requires three sets of input
information: knowledge or assumptions regarding the pathway
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2444topology and regulation; choice of a suitable mathematical
modeling framework; and data permitting parameter estimation.
Pathway Structure
As a starting point, we focused on the nigrostriatal pathway,
which is the dopamine pathway most affected in PD. The
simplified pathway diagram (Figure 1) was constructed by
integrating information from databases [21,22], literature
[23,24], and expertise provided by neurologists and biologists.
Dopamine metabolism is located primarily in the presynaptic
neuron and the synaptic cleft. Its homeostasis is controlled through
a complicated biochemical network. Tyrosine, as the precursor of
the dopamine pathway, is converted to L-DOPA by tyrosine
hydroxylase (TH), which is regarded the rate-limiting enzyme of
dopamine metabolism. DOPA decarboxylase (AADC) uses most
of the L-DOPA to synthesize the key neurotransmitter dopamine,
but L-DOPA can also be converted into the neuronal pigment
melanin. Dopamine is packed into vesicles by the vesicular
monoamine transporter (VMAT2). The packed dopamine is
subsequently released into the synaptic cleft, where released
dopamine can bind to dopamine receptors located on the
postsynaptic membrane. Alternatively, dopamine can be taken
up by the dopamine transporter (DAT) and returned back to the
cytoplasm of the presynaptic neuron. Furthermore, extracellular
dopamine can be methylated by catechol O-methyltransferase
(COMT) to 3-methoxytyramine (3-MT). Monoamine oxidase
(MAO) can oxidize cytoplasmic dopamine to 3,4-dihydroxyphe-
nylacetate (DOPAC), which COMT may convert to homovanil-
late (HVA) .
Modeling Framework
For our modeling environment we chose Biochemical Systems
Theory (BST) [25–27], because it permits mathematical analyses
and simulations of biochemical pathways under a minimal set of
assumptions and even if crucial quantitative information is lacking,
as it has been demonstrated in other, similarly complex contexts
[28–30]. BST has been described numerous times, and detailed
reviews are available [28–33]. The easy access to documentation
of theory and applications allows us to minimize the description
here; some pertinent details are given in the Supplemental
Materials S1.
The key feature of BST is the representation of processes with
products of power-law functions. This particular formulation is
solidly anchored in Taylor’s approximation theory and exhibits
three important features. First, the representation is guaranteed to
be appropriate in the vicinity of some chosen nominal point at
Figure 1. Simplified diagram of the nigrostriatal dopamine pathway, constructed from information in the literature, databases, and
expert opinion of biochemists and neurologists. Detailed lists of all metabolites, variable names in the model, abbreviations, and numerical
values are presented in Supplement Tables S1 and S2. Primary metabolites are highlighted in yellow, reactive oxygen and nitrogen species in light
red, and toxic species in light purple; X29 is dopamine-3-sulfate, which is merely a recipient of material and not explicitly modeled; it is therefore not
listed in Supplement Table S1 and S2. The ellipse shows dopamine inside vesicles. Metabolites in the synaptic cleft are indicated by dashed frames.
Solid arrows represent biochemical reactions; associated enzymes are denoted in capital italics in light blue. Dash-dotted arrows designate inhibition,
while dashed arrows with plus sign designate activation. Transport steps are represented as dashed arrows. Abbreviations of enzymes are: TH -
tyrosine hydroxylase, TYR - tyrosinase, XO - xanthine oxidase, ALDH - aldehyde dehydrogenase, MAO - monoamine oxidase, SSAO - semicarbazide-
sensitive amine oxidase, AADC - DOPA decarboxylase, DCT - dopachrome isomerase, CAT - catalase, SOD - superoxide dismutase, COMT - catechol O-
methyltransferase, GPx - glutathione peroxidase, MIF - migration inhibitory factor. Question marks refer to enzymes that are unknown or not fully
understood. Not shown in the diagram are deacetylipecoside, deacetylisoipecoside, noradrenaline, norcoclaurine, and norlaudanosoline; they are
identified as ‘‘downstream products’’.
doi:10.1371/journal.pone.0002444.g001
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shown that this vicinity can be quite large in biological systems and
that power-law representations are often sufficiently accurate for
high-percent or even fold variations in system components. In
other words, systems characterized by high variability are often
well characterized by power laws. Third, the resulting equations
are very rich in structure and can model, in principle, any
conceivable nonlinearity that has continuous derivatives [34],
including limit cycles and deterministic chaos [35].
It is customary in BST to distinguish dependent variables (Xi,
i=1,2,…,n), representing genes, proteins, metabolites, or other
components characterizing the dynamics of the system, from
independent variables (Xi, i=n+1, n+2, …, n+m), such as constant
inputs or enzyme activities, that do not change during any single
experiment. Both types of variables enter the appropriate power-
law terms of the system, but equations are only formulated for the
dependent variables. In the so-called Generalized Mass Action
(GMA) form, which we use here, a BST model thus has the format
_ X Xi~+ci1 P
nzm
j~1
X
fij1
j +...+cik P
nzm
j~1
X
fijk
j , ð1Þ
where each power-law term is composed of a rate constant c and
of all variables that directly affect the modeled process, raised to a
kinetic order exponent f. A rate constant characterizes the flux rate
between pools or variables, while a kinetic order reflects the
strength of the effect that the corresponding variable Xj has on a
given process.
If the true functions for the processes in the system are
unknown, the numerical values of the parameters in the power-law
representations (Eq. 1 and Supplement Eq. S1) are not known.
Nevertheless, the structure of the equations is completely
predictable and can be formulated symbolically from information
about which variables directly affect each process. This type of
information is often, though not always, available for metabolic
pathways, and the task of determining appropriate parameter
values remains to be one of the most significant challenges of
modeling with BST or any other model.
Parameter Estimation
Any numerical implementations and simulations of a BST
model require the identification of parameter values. Although
numerous methods have been developed over the years [30,36],
each new pathway creates its own challenges. To some degree,
kinetic information may be available in enzyme databases [21,22],
but it is still often difficult to assess to what degree kinetic
information from one organism and one set of (typically in vitro)
conditions is applicable to another organism and possibly in vivo.
Our task of developing a numerical model of dopamine
metabolism in the human brain (Fig. 1) did not allow us to use
much published data. For instance, very little information is
available on the exact concentrations of the metabolites that
contribute to dopamine metabolism. Fortunately, every parameter
in a BST model has a unique and unambiguously defined role,
which greatly facilitates model design and estimation. This is to be
seen in contrast to traditional kinetic models, which may contain
multiple parameters characterizing the same process or event. For
instance, detailed models of enzyme catalyzed mechanisms, such
as a ping-pong mechanism, may require dozens of affinity,
equilibrium, and rate constants that are associated with interme-
diate complexes, as poignantly discussed in Schultz [37]. Adding
to this complication is the fact that it is seldom a priori clear which
traditional mechanism would be most appropriate in a given
situation. In BST models, by contrast, the effect of any given
system component on any given process is uniquely described by
one kinetic order plus one rate constant for the overall turn-over
rate of the process. These differences between traditional and BST
models are crucial for the estimation of parameters, because: (1) it
is immediately clear how many parameters are to be used and how
they enter the system of equations; (2) typically fewer parameters
are to be estimated; and (3) the specific meaning of each parameter
allows the setting of biologically supported constraints. In addition,
experience with BST and other approaches suggests that systems
models are rather robust if the system structure is captured
correctly. In other words, if all connections between metabolites
and all signals are accounted for, the parameter values are not as
critical as one may think, and if a kinetic order is set as 0.75
instead of 0.6 or 1, the model responses are often still meaningful.
All these aspects render BST a powerful structure for model
implementation and estimation in the face of uncertainty.
Even with the stated advantages of BST, parameter estimation
difficult. In fact, it may well be the hardest step in the entire
modeling process. In light of the generic difficulties and the relative
robustness of BST models, we decided to construct our dopamine
model as a ‘‘relative’’ model based on expert knowledge.
Specifically, adapting strategies for assessing complex systems
from the fields of toxicology, risk assessment and evidence-based
medicine, we asked several experts on neurochemistry and
Parkinson’s disease about the relative amounts of compounds in
the dopamine system with respect to dopamine itself or to some
other, relatively well characterized compounds in the system. We
utilized this expert knowledge to estimate the relative metabolite
profile at steady state as well as the relative magnitudes of fluxes
within the dopamine system. We complemented this information
with default values for kinetic orders, as they have been used in
BST for a long time (Chapter 5 in [30]). It is clear that this type of
procedure is not as quantitative as we would like. However, there
is really not much of an alternative, and the models thus
constructed do reflect expert opinions of the dopamine metabolism
quite well [38–50]. As far as we know, the type of expert-based
parameter estimation applied here has not been used in metabolic
modeling before. To limit the parameter space further, we
assumed that all processes are of first order with respect to the
catalyzing enzyme, which is the implicit default assumption in
most kinetic models.
The results of our parameter search are reflected in Supplement
Table S1 and in the numerical models (see Supplemental Material
S2). The independent variables of the model are listed in
Supplement Table S2.
Results
Steady-State Analysis
The model of dopamine metabolism (represented in diagram form
in Figure 1) was diagnosed, analyzed, and refined according to the
guidelines provided in BST [30]. Due to the expert-based
determination of parameter values, the steady-state concentrations
and fluxes of the model were automatically consistent with expert
opinion (Supplement TableS1). Also consistent with the expert-based
flux profile, the rate constants associated with the generation of L-
DOPA from tyrosine, conversion of L-DOPA to dopamine, and
dopamine transportation turned out to have the largest magnitudes.
The dopamine model is locally stable and thus able to withstand
small perturbations. Upon perturbations to the system, some
metabolites may exhibit well-damped, small-amplitude oscilla-
tions. Such oscillations occur primarily in dopamine quinone (DA-
Q), dopamine chrome, 5,6-dihydroxyindole-2-carboxylate
(DHICA), melanin, DOPAC, and DOPAC quinone (DOPAC-Q).
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The real testing of the model occurred through simulations of
enzyme manipulations. In these simulations, local perturbations
(on enzyme activities and regulatory functions) were introduced
and the global model responses were compared to experimental
findings. In contrast to the confirmation of steady-state features,
which were used for model design, the consistency in these
dynamic experiments is by no means automatic, and because there
was no additional data fitting, the results are much more indicative
of the quality of the model or of its shortcomings.
TH, COMT, DAT, and VMAT2 were selected as primary
targets of manipulations, because experimental data are available
for comparison. Simulations addressed heterozygotes (single allele
deletion), gene knockouts (two allele deletion), gene hypomorphs
(severely impaired transcription), as well as DAT inhibition.
Striatal levels of dopamine and its two main metabolites, DOPAC
and HVA, were compiled and used for comparison with model
predictions.
Table 1 shows comparisons of experimental data and model
predictions. Here, the activities of TH and COMT were changed
through the use of heterozygote or homozygote knockouts, and
cases with or without DAT inhibition [51–53] were tested against
the resultant changes in the concentrations of dopamine, DOPAC,
and HVA. The manipulation of VMAT2 included an approxi-
mate 95% genetic reduction of expression [38]. The results
demonstrate a surprisingly high degree of accuracy of prediction,
which supports the qualitative validity of our model. For example,
relative changes in dopamine, DOPAC, and HVA levels in
response to a COMT heterozygote mutation together with 90%
DAT inhibition were predicted by the model as 15%, 90%, and
243%, respectively, while experimental measurements yielded
comparable values of 22%, 71%, and 217%. Recent findings
show that reduction of VMAT2 causes a severe reduction of
dopamine, nigrostriatal neurodegeneration, increased vulnerabil-
ity to various toxicants, and motor behavior deficits [50,54,55].
Our experimental data and model predictions revealed that
reduced VMAT2 causes adverse effects such as lowering
dopamine level, elevating toxic metabolites (cysteinyl adducts, a
marker of quinone formation as seen in reference [38]), and
exacerbating oxidative stress [38]. Equally supportive results were
found for most of the other manipulations, where the model
provided qualitatively correct and even semi-quantitatively
accurate predictions of systemic behaviors.
Some predictions, especially with respect to HVA, differ
considerably from experimental data. This relatively low accuracy
is in most cases due to our deliberate decision not to tweak
parameter values arbitrarily. Specifically, all enzymes have kinetic
orders of 1, reflecting the typical default of first-order involvement.
Deviations from this default could effectively improve accuracy of
prediction of HVA level. For example, if one simply alters the
kinetic order of COMT in the synthesis of HVA to 0.3, the relative
change on HVA in the COMT heterozygote and COMT
heterozygote/DAT 90% inhibition experiments is predicted to
be 220% and 217%, which is very similar to the experimental
findings (215% and 217%). It is unknown at this point whether
there is rationale for such an alteration, but the change in kinetic
order indicates that the model could be slightly reparameterized
for more accurate numerical results. We did not consider this
necessary at the present state of our model.
Gain Analysis
An important feature in any systems analysis is the relative
strength of control that each part of the system plays. Questions of
this type are addressed with methods of sensitivity analysis, where
one investigates output responses of the system due to small,
permanent disturbances, either in the environment or in the
system structure, which in turn is characterized by its parameters.
These kinds of sensitivity analyses allow a preliminary screening
for environmental factors and system properties that are most
critical or that could potentially be manipulated efficaciously in
order to alter important system behaviors, such as disease states.
Interpreted correctly, sensitivity analyses can aid both in the
discovery of biomarkers and the development of potential
pharmacological interventions.
It is customary in BST to distinguish the model’s steady-state
sensitivity with respect to parameter values as opposed to
independent variables. The relative change of a dependent
variable at steady state in response to a relative change in an
independent variable is specifically called a logarithmic gain (log
gain). Each gain or sensitivity value corresponds to the (positive or
negative) percent change evoked by a 1% increase in an
independent variable or a parameter.
Log gains are very useful for the assessment of the robustness of
a system, because changes in independent variables often reflect
natural fluctuations within the internal or external milieu of the
organism. In our model, independent variables include dozens of
enzymes and environmental variables that are considered constant
and at their normal value under physiological conditions
(Supplement Table S2). Among these, L-Glutamate (Glu) can be
Table 1. Changes in metabolite concentrations, relative to
wild type, in response to manipulations of components of
dopamine metabolism.
Manipulation Metabolites
Experimental
Result Prediction
TH heterozygote dopamine No change 22.68%
DOPAC No change 0.78%
HVA No change 20.94%
TH knockout dopamine 299.58% 2100.00%
DOPAC Not detected 2100.00%
HVA Not detected 2100.00%
COMT heterozygote dopamine 6.93% 18.56%
DOPAC 10.54% 18.93%
HVA 214.52% 249.10%
COMT knockout dopamine 10.64% 37.39%
DOPAC 232.95% 464.06%
HVA 2100.00% 2100.00%
COMT
heterozygote+90% DAT
inhibition
dopamine 21.97% 14.57%
DOPAC 71.46% 89.78%
HVA 217.01% 243.36%
COMT knockout+90%
DAT inhibition
dopamine 30.58% 30.25%
DOPAC 447.50% 876.77%
HVA 2100.00% 2100.00%
VMAT2 LO
# dopamine 285.42% 289.98%
DOPAC 258.00% 228.96%
HVA 258.17% 283.55%
#: VMAT2 LO mice show 95% reduction in the VMAT2 level compared to wild
type mice.
doi:10.1371/journal.pone.0002444.t001
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.NO is a reactive nitrogen species (RNS), while glutathione (GSH)
and ascorbate (ASB) are antioxidants that can alleviate oxidative
stress. The concentrations of these variables depend on diet and
the environment and are thus subject to repeated dynamic
changes. Other independent variables mainly represent enzyme
activities that are not directly linked to environmental or dietary
fluctuations, but are immediately affected by genetic variations
and possibly during disease.
Log gains were analyzed for all combinations of dependent and
independent variables and generally found unremarkable. The
entire set of gains is large, and Supplement Table S3 only shows
the most pertinent results. Of primary interest are gains of
important metabolites, reactive oxygen species (ROS), RNS, and
toxic species that are closely associated with the pathogenesis of
PD (Fig. 2). Metabolites of special interest include L-DOPA,
dopamine, dopamine in vesicles (DA-v), extracellular dopamine
(DA-e), DOPAC, extracellular DOPAC (DOPAC-e), HVA, and
melanin. ROS include O2
2.,H 2O2, extracellular H2O2 (H2O2-e),
and HO
., while RNS comprise HO
.—NO2
. and
.NO2. Toxic
species in our model are dopaquinone (DOPA-Q), 3-MT,
DOPAL, extracellular DOPAL (DOPAL-e), DOPAC-Q, and
DA-Q.
As Supplement Table S3 indicates, all gains are relatively small
in magnitude, which is typically considered a positive sign of
model robustness, but also implies that it is difficult to change
concentrations (such as for dopamine) through induced alterations
in enzyme activities. Most of the gains are small in magnitude
(,,1) so that fluctuations are effectively attenuated in almost all
cases. Among the dozens of independent variables, only AADC
has a noticeable effect on DOPA concentration, with a log gain of
21.63%, which is to be interpreted as a 1.63% relative decrease in
response to a 1% increase in AADC activity. Dopamine in all
locations (intracellular, in vesicles, or extracellular) is negatively
affected by increases in the activities of MAO and semicarbazide-
sensitive amine oxidase (SSAO), which are enzymes catalyzing the
degradation of dopamine. Outside MAO and SSAO, the vesicular
monoamine transporter (VMAT2) also affects the concentration of
DA-v and DA-e, but with positive log gains; DAT and COMT
have a slightly negative effect on DA-e. With respect to DOPAC,
only Fe
2+ has a relatively significant influence with a log gain of
20.74%. Increases in many independent variables, such as S-
Adenosyl-L-methionine (SAM), DAT, MAO, SSAO, and COMT,
negatively affect DOPAC-e. DOPAC-e is positively affected by
increases in VMAT2, extracellular monoamine oxidase (MAO-e),
and extracellular semicarbazide-sensitive amine oxidase (SSAO-e).
HVA is mainly influenced by SAM and COMT. Melanin, the
source of pigmentation in dopaminergic neurons, can be altered
by changing the concentration of MAO, SSAO, or COMT.
Oxidative stress may be assessed approximately by measuring
concentrations of ROS and RNS, and its association with
dopamine metabolism is reflected in the corresponding log gains
(Supplement Table S4). All are close to 1 or smaller in magnitude,
identifying them as unremarkable and difficult to affect.
One might ask to what degree it could be possible to reduce the
amounts of toxic species, such as DOPA-Q. Supplement Table S5,
exhibiting log gains with respect to these metabolites, indicates
that toxic species are difficult to remove. The relatively most
effective way of decreasing DOPA-Q would be an increase in the
activity of AADC with a log gain of 3.37. Reductions in Fe
2+ or
increase of COMT activity would have a similar but weaker effect.
Unduly high values of 3-MT could possibly be alleviated by
activation of extracellular aldehyde dehydrogenase (ALDH-e) or
MAO-e, or through inhibition of SAM or COMT. Increases in
VMAT2, SAM, MAO, SSAO, or COMT could moderately lessen
content of DA-Q. According to the gain analysis, it would be very
Figure 2. Interrelationships between dopamine metabolism, VMAT2, DAT, the generation of toxic species, oxidative stress and
mitochondrial dysfunction in Parkinson’s disease.
doi:10.1371/journal.pone.0002444.g002
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gains are close to zero.
While all log gains are small, it is still worth exploring the effects
of combined and larger alterations in some of the variables with
relatively higher gains. Most metabolites of the dopamine pathway
have low concentrations in the human brain, so that even small
amounts of medication would evoke relatively large deviations and
could thereby be quite efficacious. Some results of such an
exploration are shown in Table 2.
Table 2 shows that increasing VMAT2 could elevate concentra-
tions of extracellular dopamine and total dopamine, but is less
efficacious than MAO inhibition. However, MAO inhibition has
the undesired side effect of elevating some of the toxic species, such
as 3-MT, DA-Q, and DOPA-Q. Severe increases in these toxic
species are deleterious to dopaminergic neurons and may induce
neuronal degeneration. The combined targeting of VMAT2 and
MAO shows a substantial increase of dopamine while keeping the
concentrations of toxic species under control. For example, 10%
MAO inhibition together with a 50% increase in VMAT2 is
predicted to elevate extracellular dopamine by 70%, while elevating
3-MT by only 32%. The latter has to be seen in contrast to 50%
MAO inhibition alone, which raises 3-MT more than 7-fold. The
other toxic species are actually lowered by the combination
regimen. While these results are based on a preliminary model,
they indicate how a computational systems approach may aid the
screening and selection of pharmacological therapies.
Parameter Sensitivity Analysis
The parameter set of the dopamine metabolic model is
comprised of kinetic orders and rate constants. Each kinetic order
is a reflection of the strength with which a variable affects the
corresponding process, while a rate constant determines the
turnover rate of a process [25,26]. As in the case of log gains, a
sensitivity value of (positive or negative) p indicates a p% change in
some outcome measure due to a 1% increase in the parameter of
interest.
Given the large number of dependent variables and parameters,
the full set of sensitivities is immense and rather uninteresting.
Indeed, most sensitivity values are small, indicating that moderate
perturbations in model structure are essentially inconsequential.
The highest sensitivities (in a range of magnitude 5 to 10) are found
with respect to DOPAC-e. A pertinent selection of somewhat large
sensitivities is presented in Supplement Table S6. As an example,
the kinetic orders associated with dopamine degradation show
negative gains for dopamine [23.8 to 25.4], as well as for DOPA
[22.1 to 22.9], DA-v [23.8 to 25.4], DA-e [24.5 to 26.4],
DOPAC-e [27.3 to 210.2], and melanin [23.8 to 25.3]. As
another example, the sensitivity profile of DA-e ranges from 0 to
about 6.4 in absolute magnitude. DA-e is the actual transmitter of
nerve signals for movement control. Its only noteworthy sensitivities
(with respect to DA-e self-degradation and dopamine degradation
toward DOPAL) are negative. Hence, measures to decrease the
effects of dopamine, MAO, or SSAO on the reaction between
dopamine and DOPAL could potentially constitute efficacious
interventions to increase DA-e concentrations. DOPAC-e is
negatively influenced by dopamine degradation and positively by
increases in the reaction between DA-e and DOPAL-e.
As with kinetic orders, most of the sensitivities with respect to
rate constants are negligible (Supplement Table S7). An exception
is rate constant c1_0, which represents the exogenous input flux
into the dopamine metabolic system. As one might expect,
enhancements in this flux yield increases in the concentrations of
most primary metabolites especially that of melanin, with the
exception of DOPAC, which slightly decreases. Almost all other
rate constant sensitivities are of magnitude 1 or smaller.
The kinetic order and rate constant sensitivities of ROS and
RNS are shown in Supplement Tables S8 and S9. As with
enzymes and antioxidants within the cell defense system, such as
CAT, SOD, GPx, and GSH, their kinetic order sensitivities show
moderate or higher capability of scavenging those ROS and RNS.
As before, the influx to the system generally has an enhancing
effect. Not surprisingly, the sensitivities suggest that increased
degradation of dopamine would increase all ROS and RNS except
for H2O2-e, while most of ROS and RNS could be moderately
alleviated by enhancing their own degradations.
Parameter sensitivities with respect to toxic species are presented
inSupplemental TablesS10andS11.Changesinquitea few kinetic
orders could yield decreases in the concentration of DOPA-Q,
especially those parameters associated with L-DOPA conversion to
dopamine and DOPA-Q degradation to pyrrolo-quinoline quinine
(PQQ). 3-MT, DOPAL, and DOPAC-Q are most strongly affected
by changes in kinetic orders associated with their own degradations.
Increases in kinetic orders for the conversion of dopamine to
DOPAL could result in a substantial reduction of toxic DA-Q.
Table 2. Alterations in metabolite concentrations, relative to wild type, in response to MAO inhibition and increase of VMAT2.
Metabolites
50% MAO
Inhibition
50% VMAT2
Increase
50% MAO Inhibition+50%
VMAT2 Increase
10% MAO Inhibition+50%
VMAT2 Increase
10% MAO Inhibition+100%
VMAT2 Increase
DA-i 131.30% 28.72% 116.47% 5.29% 22.15%
DA-e 160.98% 43.99% 275.86% 69.83% 115.41%
DA
# 131.51% 36.38% 223.69% 57.34% 94.59%
H2O2 230.64% 28.92% 236.22% 212.85% 219.33%
H2O2-e 26.61% 17.95% 44.04% 21.64% 36.45%
HO
. 252.51% 217.48% 259.98% 224.57% 235.60%
.NO2 215.17% 29.25% 221.99% 210.98% 217.51%
DOPA-Q 145.25% 227.94% 87.68% 213.49% 233.52%
3-MT 732.53% 25.49% 719.03% 31.73% 27.26%
DOPAC-Q 242.17% 28.72% 245.88% 214.72% 220.74%
DA-Q 142.15% 227.35% 85.97% 215.16% 234.87%
#: Total amount of dopamine (intracellular, intravesicular, and extracellular).
doi:10.1371/journal.pone.0002444.t002
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concomitant effects on DOPA-Q, DOPAL-e, and DA-Q and
increasing the rate of the degradation of toxic species would
moderately alleviate their concentrations. Other than that, the
system is by and large buffered against changes in turnover rates.
Discussion
The ability of dopamine replacement to restore the primary
movement deficit in PD is striking. Unfortunately, the success of
this treatment is temporary with side effects limiting the
effectiveness. An improved understanding of the dynamics and
control of dopamine metabolism is necessary for improving
approaches to dopamine restoration therapy. The main challenge
of this endeavor is the sophistication and complexity of the
dopamine pathway, which is further confounded by the enormous
difficulties in laboratory measurement in vivo. Our education and
Western culture have trained us to subdivide complicated
problems into manageable tasks, and this strategy is very successful
if the system under investigation is linear. However, for systems
containing many nonlinear processes, as it is the case with
dopamine metabolism, dissection of the integrated system becomes
problematic, because our brain is not able to weigh the relative
importance of parallel or counteracting processes against each
other in a quantitative fashion, or to assess the strength of a control
signal against the magnitude of the flux through a pathway.
Drawing from the fields of neuroscience, neurology, and
biochemistry, we collected a large body of information character-
izing the connectivity and regulation of the dopamine pathway
and converted this information into a BST model. As described
before, we then numerically configured this model in accordance
with expert knowledge on neurochemistry of the dopamine
metabolism. Even though this procedure was at best semi-
quantitative, it allowed us to set up a BST model that was
consistent with expert knowledge. As a first step of model
diagnosis, we analyzed systemic properties at the steady state. By
design, the steady-state concentrations and fluxes reflected the
input suggested by the experts. Not as automatic, but also not very
surprising, the model turned out to be locally stable, and while
some variables exhibited oscillations, these were of small amplitude
and strongly damped. Much more interestingly, simulations of
scenarios not used for model design and implementation turned
out to be surprisingly close to experimental and clinical
observations. Some examples are revisited below.
Our model results showing that the dopamine concentration in
the brain increases if the enzyme MAO is inhibited are consistent
with clinical observations. Selegiline, a MAO inhibitor, has long
been used as a therapeutic treatment for PD [56–59]. Beyond the
prediction on ultimate effects of MAO inhibition, our results also
suggest that inhibition of MAO may have undesired side effects. In
addition to augmenting dopamine levels, reduction of MAO
activity increases the amounts of toxic species, which in turn may
contribute to the degeneration of dopaminergic neurons. It is
tempting to speculate that the less than expected beneficial effects
of Selegiline seen in the DATATOP study [60] were due to these
unforeseen deleterious effects of MAO inhibition.
Our results suggest that a combination of targets could be
considered in the development of improved drugs for PD. The
predicted adverse effects of lowering VMAT2 suggest that
increases in VMAT2 or decreases of DAT in combination with
MAO inhibition seem to have the potential of efficiently increasing
extracellular dopamine levels while minimizing side effects caused
by elevated toxic species such as 3-MT, DA-Q, and DOPA-Q
induced by sole MAO inhibition (see Table 2). Such an example is
just a small indication of the capability of a mathematical model in
exploring potential pharmacological interventions.
According to our results, a reduction in VMAT2 activity causes
DA-e and DA-v to decline. Meanwhile, the toxic species DOPA-Q
and DA-Q are elevated. These findings were confirmed by a
recent paper from our laboratory that showed mice with low
VMAT2 expression display increased formation of toxic dopamine
metabolites, increased oxidative damage in dopamine-rich areas,
and a Parkinson’s disease-like phenotype [54], again supporting
the idea that increased VMAT2 could be beneficial in the
treatment of Parkinson’s disease. Indeed, a recent human study
showed that genetic polymorphisms associated with increased
VMAT2 expression reduced the incidence of PD in women [47].
According to the model, down-regulation of VMAT2, as well as
up-regulation of DAT, can elevate the amount of melanin. This
prediction is consistent with studies of Matsunaga and others
showing that neuromelanin content is inversely correlated with
neurological degeneration in PD patients [61,62]. Neuromelanin
has the ability to bind a variety of metal ions, especially iron.
Elevation of iron, in turn, may lead to increasing concentrations of
ROS and RNS, as predicted by our model, and especially to an
elevated concentration of highly reactive hydroxyl radicals. Our
predictions on the adverse effects of iron are also supported by
several recent studies [63,64].
An immediate use for the model is the determination of ‘‘choke
points.’’ These are features of the system that, if slightly
‘‘loosened,’’ permit a higher flux of material. Primary targets of
such an analysis in our case are extracellular dopamine, which
should be increased to counteract the motor symptoms of PD, and
toxic species, which should be minimized, for instance by means of
decreased production or increased degradation. The starting point
for the identification of choke points is the analysis of sensitivities
and log gains. Essentially all sensitivities and gains in our model
are small in magnitude, which is usually viewed as a good sign,
because it affirms robustness of the model. However, low
sensitivities and gains also imply that it is difficult to alter the
system through subtle manipulations, for instance, of some of the
enzymes in the system. The model analysis identified several
kinetic orders with relatively high sensitivities, but because these
reflect structural features of enzymatic processes, they are unlikely
to present accessible targets for drug treatment. Among the rate
constants, the rate of influx to the system (into the tyrosine pool)
stands out as most significant. It remains to be seen whether this
influx can be affected efficaciously by dietary or pharmaceutical
intervention. However, its deleterious side effects, similar to those
from L-DOPA administration, must be taken into account.
The most direct targets for intervention are exogenously
supplied substrates and enzyme activities, which could at least
theoretically be altered through inhibition or other mechanisms.
These targets are usually represented in the model through
independent variables, so that log gains are more important
indicators than parameter sensitivities. In the model, almost all
gains are relatively low, which again confers a certain degree of
robustness and implies that small changes are not particularly
consequential. However, pharmaceutical or dietary treatments do
not have to be in the low-percent range, especially for brain
metabolites that are present in very small concentrations. Thus, it
could be possible to effect beneficial changes, for instance by a
combined inhibition of MAO and DAT, or inhibition of MAO
together with activation of VMAT2 (see Table 2).
It is clear that the model presented here is very preliminary. In
addition to the uncertainties during parameter estimation, the
model is based on a number of simplifying assumptions. For
instance, several metabolites are treated as independent variables,
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tional scale and must be expected to change over long time
horizons. These variables include tetrahydrobiopterin, Glu, SAM,
prostaglandin G2,
.NO, GSH, ASB, N-acetylcysteine, Fe
2+,F e
3+,
NADH, NAD+, NADPH, NADP+, VMAT2, DAT, and ATP.
Furthermore, some metabolites are not taken into account, even
though they might be of importance for the proper functioning of
the nigrostriatal dopamine pathway. Finally, some processes and
enzymes within dopamine metabolism may be missing or are not
fully understood (as indicated by question marks in Fig. 1). Thus,
the proposed model is to be considered a starting point for more
detailed and refined estimations. It may also be used as a
preliminary input module for modeling approaches elucidating
phenomena further downstream, as they are, for instance, related
to DARPP-32 signaling [14,20].
Although the model is preliminary, it exhibits a number of good
features, such as robustness and consistency with diverse
experimental and clinical observations. Its main utilization at this
point is as an exploratory tool for generating hypotheses that are to
be screened and tested later in animal models. These hypotheses
may refer to the discovery of environmental exposures, biochem-
ical or genetic variations, and different disease trajectories toward
PD. Because manipulations are infinitely easier in the model than
in an animal experiment, numeric simulations and model analyses
can be executed in a very short period of time, permitting
comprehensive screening of possible scenarios and responses [65].
Our model was initially formulated for the nigrostriatal
dopamine pathway and with emphasis on PD. However, with
slight modifications it could be applicable to other disorders in
which dopamine homeostasis is altered, as for instance in attention
deficit hyperactivity disorder. The concepts and methodology in
these cases will be unchanged, but adjustments are likely to be
necessary with regard to the numerical properties of the model and
possibly the topology of the underlying biochemical network.
Supporting Information
Materials S1 Supplements without tables
Found at: doi:10.1371/journal.pone.0002444.s001 (0.06 MB
DOC)
Table S1 Metabolite concentrations and fluxes at steady state
(relative units)
Found at: doi:10.1371/journal.pone.0002444.s002 (0.06 MB
DOC)
Table S2 List of independent variables (include environmental
factors and enzymes)
Found at: doi:10.1371/journal.pone.0002444.s003 (0.06 MB
DOC)
Table S3 Among dozens of independent variables, only DOPA
decarboxylase (AACD) significantly affects DOPA concentration,
with a log gain of 21.63%, which means that DOPA is predicted
to exhibit a 1.63% decrease in response to 1% increase in AADC
activity. Dopamine, no matter where it is located (intracellular, in
vesicles, or extracellular) is negatively affected by enhancement of
MAO or semicarbazide-sensitive amine oxidase (SSAO), which
are enzymes catalyzing the degradation of dopamine. Except for
MAO and SSAO, the vesicular monoamine transporter (VMAT2)
also influences the concentration of DA-v and DA-e, but with
positive log gains, while DAT has a negative effect on DA-e. Only
Fe2+ has a significant influence on DOPAC, with a log gain of
20.74%. Increases in many independent variables, such as S-
adenosyl-L-methionine (SAM), DAT, MAO, SSAO, and COMT
are predicted to affect DOPAC-e negatively, while VMAT2,
extracellular monoamine oxidase (MAO-e), and extracellular
semicarbazide-sensitive amine oxidase (SSAO-e), DOPAC-e have
positive log gains. HVA is mainly affected by SAM and COMT.
Melanin, the source of pigment in dopaminergic neurons, is
affected by changes in the concentrations of SAM, Fe
2+, VMAT2,
DAT, MAO, SSAO, or COMT.
# Gain values are given in
percent change due to a 1% percent change in an independent
variable.
* Gain s with absolute values less than 0.5 are discarded.
Found at: doi:10.1371/journal.pone.0002444.s004 (0.05 MB
RTF)
Table S4 Log gains of ROS and RNS in response to alterations
in independent variables
#*. Only some ROS and RNS show
significant log gains with respect to the up-regulation of
independent variables. For instance, the gain of O2
2. indicates a
1.29% relative decrease upon 1% elevation of SOD. H2O2 and
H2O2-e could not be effectively changed by alterations in any of
the independent variables. HO
. increased 1.46%, 1.13%, and
1.13% in response to 1% up-regulation of Fe
2+, MAO, and SSAO,
respectively. Increasing
.NO or Fe
2+ could promote formation of
HO
.—NO2
. and
.NO2, while increases in ASB, CAT, SOD,
COMT, or GPx alleviate HO
.—NO2
..
# Gain values are given in
percent change due to a 1% percent change in an independent
variable.
* Gains with absolute values less than 0.5 are discarded.
Found at: doi:10.1371/journal.pone.0002444.s005 (0.04 MB
DOC)
Table S5 Log gains of toxic species with respect to alterations in
independent variables
#*. The most effective way of decreasing toxic
DOPA-Q is increasing the activity of AADC; lowering Fe
2+ has a
similar but lesser effect. 3-MT could be alleviated by elevation of
extracellular aldehyde dehydrogenase (ALDH-e) or MAO-e, or
reduction of SAM or COMT. DOPAL is mainly affected by Fe
2+,
NAD
+, NADH, NADP
+, NADPH, and ALDH. Elevation of DAT,
MAO, or SSAO has the most significant negative effect on the
concentrationofDOPAL-e,whileincreasesinVMAT2,MAO-e,or
SSAO-e could promote generation of DOPAL-e. None of these
primary metabolites could significantly reduce the concentration of
DOPAC-Q. To lessen content of DA-Q, Fe
2+ should be decreased
or VMAT2, SAM, MAO, SSAO, or COMT increased. However,
all effects are only moderate.
# Gain values are given in percent
change due to a 1% percent change in an independent variable.
*
Gains with absolute values less than 0.5 are discarded.
Found at: doi:10.1371/journal.pone.0002444.s006 (0.05 MB
DOC)
Table S6 Sensitivity of primary metabolites in response to
alterations in kinetic orders
#*. DOPA shows negative gains with
respect to kinetic orders for its degradation processes, except for
the inhibition from dopamine. The sensitivity of DOPA in
response to alteration of dopamine inhibition is 3.24%, which
means 1% up-regulation of dopamine inhibition is predicted to
cause a 3.24% relative increase in DOPA. Dopamine and DA-v
have very similar sensitivity profiles for kinetic orders, with positive
values associated with DOPA degradation and negative values
associated with degradative processes of dopamine and DA-e
(especially for fluxes from dopamine to DOPAL and from DA-e to
3-MT). DA-e is the actual transmitter of nerve signals for
movement control. Its only noteworthy sensitivities (with respect
to DA-e self-degradation and dopamine degradation toward
DOPAL) are negative. Hence, measures to decrease the effects
of dopamine, MAO, or SSAO on the reaction between dopamine
and DOPAL could potentially constitute efficacious interventions
to increase DA-e concentrations. DOPAC is mainly affected by
kinetic orders for H2O2 degradation. Sensitivities of DOPAC-e
are negatively influenced by dopamine degradation and positively
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and melanin show several significant sensitivity values, mostly
associated with kinetic orders related to the degradation of DOPA,
dopamine, and DA-e.
# Sensitivity values are given in percent
change due to a 1% percent change in a parameter
* Sensitivities
with absolute values less than 0.5 are discarded.
Found at: doi:10.1371/journal.pone.0002444.s007 (0.08 MB
DOC)
Table S7 Sensitivity of primary metabolites in response to
alterations in rate constants
#*. As with kinetic orders, most of the
sensitivities with respect to rate constants are negligible in
magnitude. Of note is rate constant c120, which represents the
exogenous input flux into the dopamine metabolic system. As one
might expect, enhancements in this flux yield increases in the
concentrations of most of the primary metabolites especially that of
melanin, with the exception of DOPAC, which slightly decreases.
Almost all other rate constant sensitivities are of magnitude 1 or
smaller. DOPA is negatively affected by rate constants for
degradation of DOPA and dopamine. Dopamine, DA-v, and DA-
e have negative sensitivities with respect to the rate constant for the
reaction between dopamine and DOPAL. Increasing the transport
of dopamine into vesicles could increase the concentrations of DA-v
and DA-e, while enhancing degradation of DA-v and DA-e is
expected to lead to decreases in their concentrations, respectively.
DOPAC, DOPAC-e and HVA are mainly affected by rate
constants related to their synthesis and degradation. DOPAC-e
also has significant sensitivities with respect to rate constants for
dopamine reactions.Manyrateconstantsinfluencemelanintosome
extent but much less than c120.
# Sensitivity values are given in
percent change due to a 1% percent change in a parameter.
*
Sensitivities with absolute values less than 0.5 are discarded.
Found at: doi:10.1371/journal.pone.0002444.s008 (0.06 MB
DOC)
Table S8 Sensitivities of ROS and RNS in response to
alterations of kinetic orders
#*. Enhancing the degradation of
dopamine increases all ROS and RNS except H2O2-e, while
elevation of kinetic orders for effluxes out of DA-e reduce the
concentrations of most ROS and RNS. O2
-.,H 2O2, and H2O2-e
decrease upon up-regulation of their relevant degradation
processes. Increasing kinetic orders for degradation of DOPAC,
DOPAC-e, O2
-.,H 2O2,o rH O
. alleviates HO
. concentration. HO
.
—NO2
. and
. NO2 could be decreased by enhancing the
degradation of O2
-. or H2O2. Enzymes and antioxidants within
the cell defense system, such as CAT, SOD, GPx, and GSH,
exhibit kinetic order sensitivities that show moderate capability of
scavenging these reactive species.
Found at: doi:10.1371/journal.pone.0002444.s009 (0.05 MB
DOC)
Table S9 Increasing rate constant c120 would raise the
concentrations of all ROS and RNS, especially those of HO
.
and HO
.—NO2
.; the rate constants for degradation of dopamine
to DOPAL have similar but lesser effects. Most of ROS and RNS
could be significantly alleviated by enhancing their own degrada-
tion. HO
. could also be reduced through enhancement of H2O2
degradation. Increasing the rate constant for DOPAC autoxida-
tion would elevate HO
.—NO2
. and
.NO2, while rate constants for
O2
-. and HO
. degradation have the opposite effect.
Found at: doi:10.1371/journal.pone.0002444.s010 (0.04 MB
DOC)
Table S10 Sensitivity of toxic species in response to alteration of
kinetic orders
#*. Quite a few kinetic orders could efficaciously
decrease the concentration of DOPA-Q, especially those related to
L-DOPA conversion to dopamine and DOPA-Q degradation to
Pyrrolo-quinoline quinine (PQQ). 3-MT, DOPAL, and DOPAC-Q
have significant sensitivities with respect to kinetic orders related to
their degradation. Reductionin kinetic orders for DA-edegradation
to 3-MT could also effectively alleviate the concentration of 3-MT.
Increasing the effect of dopamine, MAO, or SSAO on dopamine
degradation could greatly alleviate the concentration of DOPAL-e;
decreasing the kinetic order for the reaction between DA-e and
DOPAL-e has a similar effect. Increases in DOPAL-e degradation
could somewhat reduce its own concentration. DA-Q shows
significant sensitivities mostly with respect to kinetic orders for the
conversion of dopamine to DOPAL.Elevationof the action of GSH
onH2O2could indirectlyresultingreatreductionsoftoxicDA-Q.
#
Sensitivity values are given in percent change due to a 1% percent
change in a parameter.
* Sensitivities with absolute values less than
3.0 are discarded.
Found at: doi:10.1371/journal.pone.0002444.s011 (0.05 MB
DOC)
Table S11 Sensitivity of toxic species in response to alteration of
rate constants
#*. Rate constant c120, which accounts for the
exogenous input flux into the dopamine system has a strong
positive effect on the concentrations of DOPA-Q, DOPAL-e, and
DA-Q. Enhancing the degradation of DOPA could decrease
DOPA-Q moderately compared with that from c120.T o
effectively reduce the concentrations of 3-MT, DOPAL, and
DOPAC-Q, their relevant rate constants for degradative processes
should be raised. DOPAL-Q could be reduced by increasing the
rate constant for conversion of dopamine to DOPAL or slowing
down degradation of DA-e to DOPAL-e. The rate constant for
DA-Q degradation has a negative effect on the concentration of
DA-Q but with smaller magnitude in comparison with c120.
#
Sensitivity values are given in percent change due to a 1% percent
change in a parameter
* Sensitivities with absolute values less than
0.5 are discarded.
Found at: doi:10.1371/journal.pone.0002444.s012 (0.06 MB
DOC)
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